BioRestorative Therapies vs Mangoceuticals
BRTX and MGRX side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BRTX and MGRX compare
BioRestorative Therapies is the larger company, worth 11 times as much as Mangoceuticals ($38.0M against $3.3M).
BioRestorative Therapies grew revenue faster over the last twelve months (−8.5% versus −38.9% for Mangoceuticals).
BioRestorative Therapies keeps more of each dollar of sales as profit, with a net margin of −3090% compared with −4791% at Mangoceuticals.
BioRestorative Therapies scores higher on the StockData Score (8 against 7 for Mangoceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BRTX | MGRX |
|---|---|---|
| Size and price | ||
| Market cap | $38.0M | $3.3M |
| Share price | $1.49 | $0.155 |
| Change, 1 year | −94.6% | −91.2% |
| Change, 5 years | −98.9% | – |
| Beta (5Y) | 1.07 | −1.27 |
| Employees | 14 | – |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 106× | 10.6× (better) |
| P/B | 12.5× | 0.3× (better) |
| Growth | ||
| Revenue growth (TTM) | −8.5% (better) | −38.9% |
| Revenue growth, 5Y average | 36.1% | – |
| Profitability | ||
| Gross margin | 92.1% (better) | 54.4% |
| Operating margin | −3975% | −3829% (better) |
| Net margin | −3090% (better) | −4791% |
| Return on equity | −241% | −95.1% (better) |
| Return on invested capital | – | −60.7% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.35 (better) | 0.18 |
| Altman Z-score | −47.28 | −6.15 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.52% | 5.6% |
| Held by insiders | 9.6% | 57.8% |
| Insider net buying, 12 months | – | −$21.2K |
| Short interest, % of float | 0.16% | 0.59% |
Go deeper
- BRTX stock overview
- BRTX income statement
- BRTX valuation and score
- MGRX stock overview
- MGRX income statement
- MGRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.